Zulfiqar Mirza, MD
Cardiovascular Disease · Lebanon, INNPI 1518021773
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 181 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 17.9% — the pattern of someone who eats at a lot of different presentations.
Across 181 payments — averaging $20.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$650
- Amgen$650
- Boehringer Ingelheim$312
- E.r. Squibb & Sons, L.L.C.$298
- Cardiovascular Systems Inc.$296
- Abbott$158
- plus $1K from 23 others
Across 34 payments — averaging $6608.68 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$159K
- E.r. Squibb & Sons, L.L.C.$36K
- Boehringer Ingelheim International GmbH$13K
- Merck$9K
- Abbott$4K
- AstraZeneca$3K
- plus $513 from 2 others
What the payments were for
- Food & beverage$3,638100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 35 | $650 |
| Amgen | 35 | $650 |
| Boehringer Ingelheim | 16 | $312 |
| E.r. Squibb & Sons, L.L.C. | 20 | $298 |
| Cardiovascular Systems Inc. | 6 | $296 |
| Abbott | 5 | $158 |
| Boston Scientific | 8 | $154 |
| Stryker | 2 | $151 |
| AstraZeneca | 8 | $141 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 8 | $131 |
| Medtronic | 2 | $90 |
| Johnson & Johnson | 5 | $87 |
| Pfizer | 4 | $68 |
| Kiniksa Pharmaceuticals International, PLC | 3 | $54 |
| Sanofi-aventis U.S. LLC | 3 | $52 |
| Biotronik Inc. | 2 | $48 |
| Altathera Pharmaceuticals LLC | 2 | $41 |
| Shockwave Medical, Inc | 2 | $39 |
| Esperion Therapeutics, Inc. | 3 | $38 |
| Daiichi Sankyo Inc. | 2 | $32 |
| Abiomed | 2 | $31 |
| EKOS Corporation | 1 | $17 |
| Scpharmaceuticals Inc. | 1 | $17 |
| Kaleo, Inc. | 1 | $16 |
| Edwards Lifesciences | 1 | $15 |
| Merck | 1 | $15 |
| Regeneron Healthcare Solutions, Inc. | 1 | $14 |
| Philips North America LLC | 1 | $13 |
| Teleflex LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,638 in reported general payments places this provider in the 55th percentile of 408 cardiovascular disease providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 366 | $331,772 |
| Repatha SureclickEvolocumab | 84 | $58,422 |
| JardianceEmpagliflozin | 29 | $36,318 |
| BrilintaTicagrelor | 31 | $29,524 |
| EntrestoSacubitril/Valsartan | 20 | $28,163 |
| Ranolazine ErRanolazine | 274 | $21,531 |
| VascepaIcosapent Ethyl | 20 | $9,475 |
| Metoprolol Succinate | 557 | $4,649 |
| ClopidogrelClopidogrel Bisulfate | 470 | $4,440 |
| Atorvastatin Calcium | 320 | $2,266 |
| Propafenone Hcl ErPropafenone Hcl | 16 | $1,946 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 59 | $1,780 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 205 | $1,444 |
| Rosuvastatin Calcium | 173 | $1,437 |
| Amlodipine Besylate | 156 | $1,012 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $68 | $331,772366 claims |
| Boehringer IngelheimJardiance | $312 | $36,31829 claims |
| AstraZenecaBrilinta | $141 | $29,52431 claims |
| NovartisEntresto | $650 | $28,16320 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 408 cardiovascular disease providers in Indiana.
Other cardiovascular disease in Lebanon
- John MillerIndianapolis$354K
- David KovacichIndianapolis$327K
- Wai LeeElkhart$321K
- Anas SafadiHobart$295K
- Lawrence RinkBloomington$280K
- Vijay RaoIndianapolis$247K
- Steven SteinhublLafayette$247K
- Atul ChughIndianapolis$242K
- James TrippiIndianapolis$239K
- Christopher HealyIndianapolis$209K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.